Mechanisms of Atrial Pathoelectrophysiology in HCM

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07454135

Acronym

MAP HCM

Enrollment

Registered

2026-03-06

Start date

2026-05-26

Completion date

2027-09-30

Last updated

2026-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation (AF), Hypertrophic Cardiomyopathy (HCM)

Keywords

hypertrophic cardiomyopathy, atrial fibrillation

Brief summary

This study aims to learn why atrial fibrillation (AF), a type of irregular heartbeat, happens more often and is harder to treat in people with hypertrophic cardiomyopathy (HCM). HCM is an inherited condition where the heart muscle is thicker than usual. Researchers will study electrical signals from the heart and advanced heart imaging. By doing this, they hope to better understand how AF behaves in people with HCM and why treatments may not work as well for them. The information from this study may help improve future treatments for people who have both HCM and AF.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Paroxysmal or persistent atrial fibrillation * Diagnosis of hypertrophic cardiomyopathy * Patient planning to proceed to atrial fibrillation ablation following clinical consultation * Age 18-80 years * Able and willing to provide written informed consent * Able and willing to comply with study follow up requirements

Exclusion criteria

* Any clinical contra-indication to ablation * Any disease limiting life expectancy to \<1 year * Potential participant currently pregnant or breast feeding * Contraindication to MRI including renal dysfunction (eGFR\<30ml/min) * Unable to understand verbal or written explanations given in English

Design outcomes

Primary

Measure	Time frame
Changes in bipolar voltage, conduction velocity, refractory periods and conduction divergence of the atria in patients with HCM and AF compared to patients with AF and structurally normal hearts	At the time of the clinical ablation procedure

Secondary

Measure	Time frame
Correlatation between the bipolar voltage in the atria with directly measured left atrial pressure, extent of late gadolinium enhancement and ventricular extracellular volume .	At the time of clinical ablation procedure
Reduction in AF inducibility in silico models following simulated ablation	Based on measurements taken during the clinical ablation procedure

Countries

United Kingdom

Outcome results